Condition
Metastatic Castration-Resistant Prostate Cancer
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 38 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
38 shownClinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate CancerNCT07798778 · 2026-07-30
RECRUITINGA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerNCT07287150 · 2026-03-11
RECRUITINGA Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT06842498 · 2026-02-22
RECRUITINGA Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate CancerNCT07339267 · 2026-01-20
RECRUITINGA Phase I Trial of A-CAR032 in Participants With mCRPCNCT07344311 · 2026-01-13
RECRUITINGA Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerNCT07005154 · 2025-08-19
RECRUITINGTreatment of Patients With Progressive mCRPC With 177Lu-PSMA-617NCT06972628 · 2025-05-23
RECRUITINGA Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate CancerNCT06879041 · 2025-03-10
RECRUITINGA Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) StudyNCT06531499 · 2024-11-11
RECRUITINGA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779 · 2024-10-22
RECRUITINGZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate CancerNCT04986423 · 2021-09-08
RECRUITINGREGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult ParticipantsNCT07850921 · 2027-06-28
NOT_YET_RECRUITINGA Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate CancerNCT06318273 · 2024-03-08
ACTIVE_NOT_RECRUITINGA Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)NCT06136598 · 2024-01-30
COMPLETEDA Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)NCT06104449 · 2023-11-14
COMPLETEDXmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate CancerNCT05005728 · 2021-10-22
COMPLETEDCATCH-R: A Rollover Study to Provide Continued Access to RucaparibNCT04676334 · 2021-03-22
COMPLETEDStudy Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal TreatmentNCT04647526 · 2021-02-25
ACTIVE_NOT_RECRUITINGStudy of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate CancerNCT04666129 · 2021-02-18
COMPLETEDAbemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate CancerNCT04408924 · 2021-01-20
COMPLETEDEnzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate CancerNCT04419402 · 2020-08-17
ACTIVE_NOT_RECRUITINGPRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEnNCT04256993 · 2020-02-15
COMPLETEDOnvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate CancerNCT03414034 · 2018-08-14
COMPLETEDStudy to Evaluate CCS1477 in Advanced TumoursNCT03568656 · 2018-07-23
COMPLETEDStudy to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate CancerNCT03437941 · 2018-02-20
TERMINATEDA Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerNCT03137758 · 2017-07-24
TERMINATEDA Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate CancerNCT02711956 · 2016-12-01
COMPLETEDStudy of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)NCT02861573 · 2016-11-17
ACTIVE_NOT_RECRUITINGA Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate CancerNCT02705469 · 2016-05-01
COMPLETEDA Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade TherapyNCT02405858 · 2015-04-10
COMPLETEDSequencing Abiraterone and Enzalutamide in mCRPCNCT02125357 · 2014-09-01
COMPLETEDA Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate CancerNCT02123758 · 2014-07-09
ACTIVE_NOT_RECRUITINGA Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate CancerNCT02116582 · 2014-05-23
COMPLETEDDual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) PatientsNCT02091531 · 2014-03-01
COMPLETEDA Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerNCT01663415 · 2012-08-01
WITHDRAWNA Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer PatientsNCT01650194 · 2012-07-09
COMPLETEDPre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)NCT05650476
AVAILABLEProvide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyNCT01606982
APPROVED_FOR_MARKETINGCommon interventions
EnzalutamideDRUG12Abiraterone AcetateDRUG6PrednisoneDRUG6AbirateroneDRUG4ZEN003694DRUG3ASP5541DRUG2DexamethasoneDRUG2DocetaxelDRUG2HydrocortisoneDRUG2OpevesostatDRUG2PlaceboDRUG2PrednisoloneDRUG2[Lu-177]-PNT2002DRUG1AAA617DRUG1ABBV-969DRUG1AbemaciclibDRUG1Abiraterone acetate 1000 mgDRUG1Administering Lutetium-177-PSMA-617 (PLUVICTO)DRUG1Adrenocorticotropic hormoneDRUG1ApalutamideDRUG1AtezolizumabDRUG1AZD2275DRUG1AZD2284DRUG1AZD2287DRUG1Belzutifan 120mgBIOLOGICAL1
Leading sponsors
Astellas Pharma Global Development, Inc.
5
Merck Sharp & Dohme LLC
3
Zenith Epigenetics
3
Pfizer
2
AbbVie
1
Affiliated Hospital of Jiangnan University
1
Aragon Pharmaceuticals, Inc.
1
Astellas Pharma Europe B.V.
1
AstraZeneca
1
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
1
Bayer
1
British Columbia Cancer Agency
1
Cardiff Oncology
1
CellCentric Ltd.
1
Corcept Therapeutics
1
Trial status mix
COMPLETED16
RECRUITING11
ACTIVE_NOT_RECRUITING5
TERMINATED2
APPROVED_FOR_MARKETING1
AVAILABLE1
NOT_YET_RECRUITING1
WITHDRAWN1
Phase mix
PHASE218
PHASE116
PHASE33
PHASE42
EARLY_PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.